India's second-largest pharmaceuticals firm Aurobindo Pharma is planning to significantly reduce raw material imports from China to mitigate the risk of supply chains disruptions. It currently procures around 55% of its material from China. The company is also planning to shift the manufacturing of some of its pharmaceutical formulations from India to a newly built facility in China.